|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019588,
umls-concept:C0023434,
umls-concept:C0030705,
umls-concept:C0032105,
umls-concept:C0034665,
umls-concept:C0042196,
umls-concept:C0086045,
umls-concept:C0087111,
umls-concept:C0184511,
umls-concept:C0205217,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1995-12-18
|
|
pubmed:abstractText |
Patients with B cell chronic lymphocytic leukemia (B-CLL) have decreased capacity to mount relevant antibody responses upon immunization, and development of hypogammaglobulinemia is part of the natural history of the disease. We investigated the influence of histamine type-2 (H2) receptor blockade by ranitidine on the in vivo antibody production in B-CLL patients following vaccination. Anti-polysaccharide antibodies in B-CLL patients, vaccinated with a tetanus-toxoid conjugated vaccine against Haemophilus influenzae type-B (Hib), reached long-term protective levels in more than 90% of B-CLL patients randomized to ranitidine treatment, as compared to 43% of the untreated patients (P = 0.024). No difference in the response to vaccination against influenza virus types A and B protein could be detected between the two groups. Plasma histamine levels were 2-fold to 20-fold higher in 23 out of 31 B-CLL patients, compared to normal controls, and these levels showed a significant positive correlation to disease duration. These findings indicate the possibility of improving in vivo antibody production against a highly relevant pathogen in B-CLL patients by histamine type-2 receptor blockade, and the combined finding of an immune-stimulatory effect of ranitidine and increased plasma histamine levels, strongly suggests the involvement of histamine in the pathogenesis of B-CLL immunodeficiency.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Haemophilus Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine H2 Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-3,
http://linkedlifedata.com/resource/pubmed/chemical/Ranitidine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, IgE
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1902-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7475282-Adjuvants, Immunologic,
pubmed-meshheading:7475282-Adult,
pubmed-meshheading:7475282-Aged,
pubmed-meshheading:7475282-Antibodies, Bacterial,
pubmed-meshheading:7475282-Cells, Cultured,
pubmed-meshheading:7475282-Female,
pubmed-meshheading:7475282-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:7475282-Haemophilus Vaccines,
pubmed-meshheading:7475282-Histamine,
pubmed-meshheading:7475282-Histamine H2 Antagonists,
pubmed-meshheading:7475282-Humans,
pubmed-meshheading:7475282-Interleukin-3,
pubmed-meshheading:7475282-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:7475282-Lymphocyte Activation,
pubmed-meshheading:7475282-Male,
pubmed-meshheading:7475282-Middle Aged,
pubmed-meshheading:7475282-Ranitidine,
pubmed-meshheading:7475282-Receptors, IgE,
pubmed-meshheading:7475282-Vaccination
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
Department of Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
